CN107796674A - A kind of method assessed using the damage of animal isolated cornea long-term cultivation model evaluation eye irritation and repair - Google Patents
A kind of method assessed using the damage of animal isolated cornea long-term cultivation model evaluation eye irritation and repair Download PDFInfo
- Publication number
- CN107796674A CN107796674A CN201710538216.7A CN201710538216A CN107796674A CN 107796674 A CN107796674 A CN 107796674A CN 201710538216 A CN201710538216 A CN 201710538216A CN 107796674 A CN107796674 A CN 107796674A
- Authority
- CN
- China
- Prior art keywords
- cornea
- damage
- corneal
- repair
- turbidity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004087 cornea Anatomy 0.000 title claims abstract description 305
- 230000006378 damage Effects 0.000 title claims abstract description 142
- 230000008439 repair process Effects 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 56
- 238000011156 evaluation Methods 0.000 title claims abstract description 54
- 206010015946 Eye irritation Diseases 0.000 title claims abstract description 28
- 231100000013 eye irritation Toxicity 0.000 title claims abstract description 28
- 241001465754 Metazoa Species 0.000 title claims abstract description 22
- 230000007774 longterm Effects 0.000 title claims abstract description 22
- 239000000126 substance Substances 0.000 claims abstract description 53
- 208000028006 Corneal injury Diseases 0.000 claims abstract description 39
- 238000001514 detection method Methods 0.000 claims abstract description 39
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000002474 experimental method Methods 0.000 claims abstract description 17
- 238000011160 research Methods 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000011159 matrix material Substances 0.000 claims abstract description 6
- 238000007619 statistical method Methods 0.000 claims abstract description 6
- 230000036259 sexual stimuli Effects 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 52
- 235000015097 nutrients Nutrition 0.000 claims description 45
- 238000012360 testing method Methods 0.000 claims description 42
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 40
- 208000027418 Wounds and injury Diseases 0.000 claims description 38
- 230000002757 inflammatory effect Effects 0.000 claims description 38
- 208000014674 injury Diseases 0.000 claims description 36
- 238000004043 dyeing Methods 0.000 claims description 31
- 239000007850 fluorescent dye Substances 0.000 claims description 27
- 238000005259 measurement Methods 0.000 claims description 27
- 239000011149 active material Substances 0.000 claims description 26
- 230000008859 change Effects 0.000 claims description 23
- 210000000981 epithelium Anatomy 0.000 claims description 23
- 210000005252 bulbus oculi Anatomy 0.000 claims description 22
- 229960002143 fluorescein Drugs 0.000 claims description 22
- 210000003560 epithelium corneal Anatomy 0.000 claims description 21
- 239000012981 Hank's balanced salt solution Substances 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 20
- 230000014759 maintenance of location Effects 0.000 claims description 19
- 102000003940 Occludin Human genes 0.000 claims description 18
- 108090000304 Occludin Proteins 0.000 claims description 18
- 229940020947 fluorescein sodium Drugs 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 210000001508 eye Anatomy 0.000 claims description 16
- 230000000638 stimulation Effects 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 14
- 229920006361 Polyflon Polymers 0.000 claims description 13
- 238000011084 recovery Methods 0.000 claims description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 12
- 230000007547 defect Effects 0.000 claims description 12
- 210000003038 endothelium Anatomy 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 10
- 102000011154 Tight junction protein ZO-1 Human genes 0.000 claims description 9
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 claims description 9
- 230000004888 barrier function Effects 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000007689 inspection Methods 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 239000004809 Teflon Substances 0.000 claims description 8
- 229920006362 Teflon® Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 230000036732 histological change Effects 0.000 claims description 8
- 238000011532 immunohistochemical staining Methods 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 230000035699 permeability Effects 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 230000004890 epithelial barrier function Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000011017 operating method Methods 0.000 claims description 7
- 108090001007 Interleukin-8 Proteins 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003855 balanced salt solution Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000010562 histological examination Methods 0.000 claims description 6
- 238000007654 immersion Methods 0.000 claims description 6
- 210000001232 limbus corneae Anatomy 0.000 claims description 6
- 210000004279 orbit Anatomy 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 210000003786 sclera Anatomy 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 238000012136 culture method Methods 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 5
- 229960004319 trichloroacetic acid Drugs 0.000 claims description 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 4
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 4
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 4
- 238000002679 ablation Methods 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 229960003942 amphotericin b Drugs 0.000 claims description 4
- 244000309466 calf Species 0.000 claims description 4
- 210000003683 corneal stroma Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000001543 one-way ANOVA Methods 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 4
- -1 proliferation factor Proteins 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- 238000011179 visual inspection Methods 0.000 claims description 4
- 102000000905 Cadherin Human genes 0.000 claims description 3
- 108050007957 Cadherin Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000002561 chemical irritant Substances 0.000 claims description 3
- 238000012549 training Methods 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 2
- 229960002986 dinoprostone Drugs 0.000 claims description 2
- 230000008556 epithelial cell proliferation Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000002962 histologic effect Effects 0.000 claims description 2
- 238000012308 immunohistochemistry method Methods 0.000 claims description 2
- 230000000670 limiting effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 2
- 229940108325 retinyl palmitate Drugs 0.000 claims description 2
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 2
- 239000011769 retinyl palmitate Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000003307 slaughter Methods 0.000 claims description 2
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims description 2
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 1
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 1
- 101150031350 Cxcl2 gene Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 abstract description 6
- 230000000254 damaging effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000002085 irritant Substances 0.000 abstract description 3
- 231100000021 irritant Toxicity 0.000 abstract description 3
- 238000000053 physical method Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 9
- 230000001771 impaired effect Effects 0.000 description 8
- 210000001747 pupil Anatomy 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 6
- 239000003570 air Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 206010018325 Congenital glaucomas Diseases 0.000 description 4
- 206010012565 Developmental glaucoma Diseases 0.000 description 4
- 208000007157 Hydrophthalmos Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 4
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 4
- 201000001024 buphthalmos Diseases 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 210000003934 vacuole Anatomy 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000003905 agrochemical Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000004879 turbidimetry Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000020564 Eye injury Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 206010023683 lagophthalmos Diseases 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000003500 flue dust Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
- G01N27/041—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
- G01N27/20—Investigating the presence of flaws
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5421—IL-8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7004—Stress
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710538216.7A CN107796674B (en) | 2017-07-04 | 2017-07-04 | Method for evaluating eye irritation injury and repair by long-term culture of animal cornea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710538216.7A CN107796674B (en) | 2017-07-04 | 2017-07-04 | Method for evaluating eye irritation injury and repair by long-term culture of animal cornea |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107796674A true CN107796674A (en) | 2018-03-13 |
CN107796674B CN107796674B (en) | 2021-03-16 |
Family
ID=61531042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710538216.7A Active CN107796674B (en) | 2017-07-04 | 2017-07-04 | Method for evaluating eye irritation injury and repair by long-term culture of animal cornea |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107796674B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109321629A (en) * | 2018-09-12 | 2019-02-12 | 黄健聪 | A kind of in-vitro method using the evaluation light injury of isolated cornea organ |
CN110568173A (en) * | 2019-07-26 | 2019-12-13 | 广州市华代生物科技有限公司 | Method for predicting eye irritation by using combination of multiple corneal structural cells |
CN112574884A (en) * | 2020-11-19 | 2021-03-30 | 深圳先进技术研究院 | Multifunctional organ chip based on microfluidic technology, preparation method and application thereof |
CN113974888A (en) * | 2021-11-11 | 2022-01-28 | 苏州药明康德新药开发有限公司 | Preparation method of rat disease model of neurotrophic keratitis |
WO2022104626A1 (en) * | 2020-11-19 | 2022-05-27 | 深圳先进技术研究院 | Micro-fluidic technology-based multifunctional organ chip, preparation method therefor and use thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1615143A (en) * | 2002-01-14 | 2005-05-11 | 亨利·福特卫生系统 | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
CN101384704A (en) * | 2005-10-12 | 2009-03-11 | 细胞生物工程公司 | Resorbable cornea button |
CN103052364A (en) * | 2010-07-30 | 2013-04-17 | 诺瓦提斯公司 | Silicone hydrogel lenses with water-rich surfaces |
CN103550117A (en) * | 2013-10-18 | 2014-02-05 | 上海润生生物技术有限公司 | Beauty and skin care product capable of promoting skin repairation and regeneration as well as preparation method and application thereof |
CN103800894A (en) * | 2014-03-03 | 2014-05-21 | 山东省眼科研究所 | Application of CNTF to corneal limbal stem cell proliferation and corneal epithelium damage repair |
CN105838672A (en) * | 2016-04-29 | 2016-08-10 | 上海市第十人民医院 | Stem cell induced culture solution used for eyes and preparation method and application thereof |
US20170029773A1 (en) * | 2015-07-30 | 2017-02-02 | Postech Academy-Industry Foundation | Method for differentiation into biocompatible keratocyte progenitor cells and keratocyte progenitor cell composition |
-
2017
- 2017-07-04 CN CN201710538216.7A patent/CN107796674B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1615143A (en) * | 2002-01-14 | 2005-05-11 | 亨利·福特卫生系统 | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
CN101384704A (en) * | 2005-10-12 | 2009-03-11 | 细胞生物工程公司 | Resorbable cornea button |
CN103052364A (en) * | 2010-07-30 | 2013-04-17 | 诺瓦提斯公司 | Silicone hydrogel lenses with water-rich surfaces |
CN103550117A (en) * | 2013-10-18 | 2014-02-05 | 上海润生生物技术有限公司 | Beauty and skin care product capable of promoting skin repairation and regeneration as well as preparation method and application thereof |
CN103800894A (en) * | 2014-03-03 | 2014-05-21 | 山东省眼科研究所 | Application of CNTF to corneal limbal stem cell proliferation and corneal epithelium damage repair |
US20170029773A1 (en) * | 2015-07-30 | 2017-02-02 | Postech Academy-Industry Foundation | Method for differentiation into biocompatible keratocyte progenitor cells and keratocyte progenitor cell composition |
CN105838672A (en) * | 2016-04-29 | 2016-08-10 | 上海市第十人民医院 | Stem cell induced culture solution used for eyes and preparation method and application thereof |
Non-Patent Citations (9)
Title |
---|
J.L. UBELS ET AL.: "Corneal permeability in a redesigned corneal holder for the bovine cornea opacity and permeability assay", 《TOXICOLOGY IN VITRO》 * |
LAURIE SCOTT ET AL.: "A proposed eye irritation testing strategy to reduce and replace in vivo studies using bottom-up and top-down approaches", 《TOXICOLOGY IN VITRO》 * |
刘东乐等: "神经营养因子促进角膜上皮损伤修复的研究进展", 《眼科新进展》 * |
彭艳阳等: "重组人表皮生长因子和碱性成纤维生长因子促进人角膜上皮细胞的增殖", 《中国组织工程研究》 * |
王晓杰: "重组人角质细胞生长因子-2克隆表达及其对角膜损伤修复机制研究", 《中国博士论文全文数据库》 * |
秦瑶等: "《日用化学品安全评价技术创新——替代方法》专题五 牛角膜浑浊和渗透性实验应用于个人护理产品评价的案例分析", 《日用化学品学科》 * |
程树军: "《日用化学品安全评价技术创新—替代方法》专题序", 《日用化学品学科》 * |
陈彧等: "《日用化学品安全评价技术创新——替代方法》专题六 利用牛角膜浑浊渗透性方法检测纸质卫生用品对皮肤刺激性研究", 《日用化学品科学》 * |
陈彧等: "结合组织学评分的牛角膜浑浊和渗透性方法研究", 《日用化学工业》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109321629A (en) * | 2018-09-12 | 2019-02-12 | 黄健聪 | A kind of in-vitro method using the evaluation light injury of isolated cornea organ |
CN110568173A (en) * | 2019-07-26 | 2019-12-13 | 广州市华代生物科技有限公司 | Method for predicting eye irritation by using combination of multiple corneal structural cells |
CN110568173B (en) * | 2019-07-26 | 2022-09-27 | 广州市华代生物科技有限公司 | Method for predicting eye irritation by using combination of various corneal structural cells |
CN112574884A (en) * | 2020-11-19 | 2021-03-30 | 深圳先进技术研究院 | Multifunctional organ chip based on microfluidic technology, preparation method and application thereof |
WO2022104626A1 (en) * | 2020-11-19 | 2022-05-27 | 深圳先进技术研究院 | Micro-fluidic technology-based multifunctional organ chip, preparation method therefor and use thereof |
CN113974888A (en) * | 2021-11-11 | 2022-01-28 | 苏州药明康德新药开发有限公司 | Preparation method of rat disease model of neurotrophic keratitis |
Also Published As
Publication number | Publication date |
---|---|
CN107796674B (en) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107796674A (en) | A kind of method assessed using the damage of animal isolated cornea long-term cultivation model evaluation eye irritation and repair | |
Tyzzer | The histology of the skin lesions in varicella | |
US6645715B1 (en) | Artificial cornea | |
Joel | Stimulation of metabolism of rat brown adipose tissue by addition of lipolytic hormones in vitro | |
CN107245509A (en) | A kind of method that eye irritation is detected using in vitro animal corneal model multi-parameter | |
US7553664B2 (en) | Three-dimensional skin model | |
CN104548209B (en) | Tissue-engineered epidermis and preparation method thereof | |
Zhang et al. | Comparison of riboflavin/ultraviolet-A cross-linking in porcine, rabbit, and human sclera | |
CN112033944B (en) | Method for evaluating skin irritation of cosmetics | |
US10993968B2 (en) | Methods and articles of manufacture for cosmetic results | |
CN104288837B (en) | A kind of acellular dermal matrix and its production and use | |
Babar et al. | Cosmetic preservatives as therapeutic corneal and scleral tissue cross-linking agents | |
CN114317661B (en) | Method for preparing multiple active collagen | |
CN105997625B (en) | A kind of moist newborn and its application for child skin mucous membrane operational maintenance | |
Yu et al. | Early histological and ultrastructural changes in expanded murine scalp | |
CA1261718A (en) | Method for testing biocompatibility | |
CN105087466B (en) | The culture medium and method that inducing umbilical cord mesenchymal stem breaks up to corneal epithelial cell | |
CN109321629A (en) | A kind of in-vitro method using the evaluation light injury of isolated cornea organ | |
Heywood et al. | Towards objectivity in the assessment of eye irritation | |
CN102178936B (en) | Methods for preparing collagen oleostock and moistening eyedrops | |
Hovakimyan et al. | Matrix-based regenerating agent for corneal wound healing after collagen cross-linking | |
CN104007057A (en) | Skin stress volume evaluating method | |
CN101487839B (en) | Method for detecting anti-anaphylaxis function of compound | |
CN110988316A (en) | Anti-irritation in-vitro evaluation method adopting chick embryo chorioallantoic membrane | |
Marks et al. | Fibroblast-mediated contraction in actinically exposed and actinically protected aging skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 510623 block C1, No.39, Huaming Road, Zhujiang New Town, Guangzhou City, Guangdong Province Applicant after: Cheng Shujun Applicant after: Guangzhou Customs Technology Center Address before: 510623 block C1, No.39, Huaming Road, Zhujiang New Town, Guangzhou City, Guangdong Province Applicant before: Cheng Shujun Applicant before: INSPECTION & QUARANTINE TECHNOLOGY CENTER OF GUANGDONG ENTRY-EXIT INSPECTION & QUARANTINE BUREAU |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210209 Address after: 510623 block C1, No.39, Huaming Road, Zhujiang New Town, Guangzhou City, Guangdong Province Applicant after: Cheng Shujun Applicant after: GUANGZHOU HUADAI BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 510623 block C1, No.39, Huaming Road, Zhujiang New Town, Guangzhou City, Guangdong Province Applicant before: Cheng Shujun Applicant before: Guangzhou Customs Technology Center |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for long-term culture of animal cornea to evaluate eye irritation injury and repair Effective date of registration: 20220620 Granted publication date: 20210316 Pledgee: Bank of China Limited Guangzhou Development Zone Branch Pledgor: GUANGZHOU HUADAI BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2022980008198 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |